William Blair downgraded Icosavax (ICVX) to Market Perform from Outperform, calling the company’s agreement to be acquired by AstraZeneca (AZN) a “successful exit.”
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ICVX: